Colorectal cancer staging determines how far the disease has spread, directly shaping every treatment decision from surgery to chemotherapy. Healthcare providers establish this stage using imaging scans, tissue biopsies, and surgical findings to determine how deeply the tumour has grown, whether nearby lymph nodes are affected, and whether the cancer has spread to other parts of the body.
Ultimately, this thorough assessment guides your medical team’s recommendations and helps set realistic expectations for your treatment journey.
The TNM Classification System
Colorectal cancer staging uses the TNM system, an internationally recognised framework that looks at three key aspects of how far the cancer has spread.
T (Tumour)
The T category describes how deeply the primary tumour has grown into the bowel wall. Think of the colon and rectum as having several layers, from the innermost lining to the outermost covering, and the T stage simply tells doctors how many of those layers the tumour has penetrated.
- Tis: Cancer cells are still confined to the innermost lining only (very early stage, sometimes called carcinoma in situ)
- T1: The tumour has grown into the second layer just beneath the surface lining
- T2: The tumour has reached the main muscle layer of the bowel wall
- T3: The tumour has grown through the muscle layer into the surrounding fatty tissue
- T4: The tumour has pushed through the outermost covering of the bowel (T4a), or has directly grown into a neighbouring organ or structure (T4b)
N (Nodes)
The N category tells doctors whether cancer has spread to nearby lymph nodes, small, bean-shaped glands that are part of the body’s immune system and act like filtering stations. Cancer cells can travel through these channels and settle in the nodes near the bowel.
- N0: No cancer found in nearby lymph nodes
- N1: Cancer found in 1–3 nearby lymph nodes (N1a: 1 node; N1b: 2–3 nodes; N1c: small clumps of cancer cells found in the surrounding tissue rather than inside a lymph node, this still places the cancer at Stage III)
- N2: Cancer found in 4 or more nearby lymph nodes (N2a: 4–6 nodes; N2b: 7 or more nodes)
M (Metastasis)
The M category identifies whether the cancer has spread beyond the bowel to other parts of the body, most commonly the liver or lungs.
- M0: No spread to distant parts of the body detected
- M1: Cancer has reached distant organs or tissues, further described as:
- M1a: Spread to just one distant organ or area, without involving the lining of the abdominal cavity
- M1b: Spread to two or more distant organs or areas, without involving the abdominal lining
- M1c: Spread to the lining of the abdominal cavity (called the peritoneum), with or without spread to other organs. This generally carries a more serious outlook than M1a or M1b
Stage Groupings
The T, N, and M findings are combined into an overall stage from 0 to IV, which gives doctors and patients a clearer picture of how advanced the cancer is and what treatment is likely needed.
- Stage 0: The cancer is still entirely within the innermost bowel lining and can usually be removed completely during a colonoscopy, without the need for further surgery.
- Stage I: The tumour has grown deeper into the bowel wall but has not reached the lymph nodes or spread elsewhere. Surgery to remove the affected section of bowel is usually the main treatment.
- Stage IΙ: The cancer has grown through the outer wall of the bowel but has not yet reached the lymph nodes. Treatment decisions at this stage depend on whether certain features in the tissue suggest a higher chance of the cancer returning.
- Stage IΙI: The cancer has reached nearby lymph nodes, regardless of how deeply the tumour has grown. Post-surgery chemotherapy is a standard recommendation at this stage to help reduce the potential risk of the cancer coming back.
- Stage IV: The cancer has spread to other parts of the body. Stage IVA means it has reached one distant area; Stage IVB means two or more areas are involved; Stage IVC means the lining of the abdominal cavity is affected. Treatment options range from surgery aimed at a cure for selected patients with limited spread, to chemotherapy, targeted medicines, and immunotherapy for more widespread disease.
Diagnostic Tools for Accurate Staging
Imaging Studies
- CT scanning (a type of detailed X-ray scan) of the abdomen and pelvis, and the chest when needed, is the main imaging tool used to stage colorectal cancer. It helps identify where the tumour is, how large it is, whether nearby lymph nodes look affected, and whether the cancer has spread to organs like the liver or lungs. CT colonography (sometimes called a virtual colonoscopy) is a related but different tool, mainly used to check the inside of the bowel for polyps when a standard colonoscopy cannot be completed; it is not the primary test used for staging.
- MRI scanning (which uses magnetic fields rather than radiation to produce detailed pictures of the body’s internal structures) is particularly valuable for rectal cancer. It gives a detailed picture of how deeply the tumour has grown into the rectal wall and how close it is to the surrounding tissue and muscle layers. This information helps doctors decide whether treatment before surgery, such as radiotherapy or chemotherapy, is needed first.
- PET-CT scanning combines two types of imaging to show both the body’s structure and how active cancer cells are. It is especially helpful for identifying small areas of spread that might not show up clearly on a standard CT scan, and is often used when the team suspects the cancer may have spread further.
Tissue Analysis
During a colonoscopy, the doctor takes a small tissue sample (a biopsy) from the tumour. A specialist doctor then examines this sample under a microscope to confirm the diagnosis and assess how the cancer cells look, including how abnormal they appear and what their molecular make-up is.
CEA (carcinoembryonic antigen) blood test measures a protein that colorectal cancers often release into the bloodstream. It is not used to determine the stage on its own, but the result before treatment begins acts as a useful reference point for monitoring how well treatment is working and whether the cancer returns later.
Surgical Staging
After the operation, the removed tissue is carefully examined by a specialist. Doctors assess how deeply the tumour grew, check the lymph nodes for cancer cells, and confirm whether the edges of the removed tissue are clear of cancer. This post-surgery assessment often provides more precise information than pre-operative scans and may influence whether additional treatment is recommended.
How Staging Influences Treatment Planning
The stage of colorectal cancer directly guides the medical team’s approach, whether that means surgery alone, chemotherapy, radiotherapy, targeted medicines, or a combination.
Surgery Considerations
The extent of surgery depends on the stage and location of the tumour. Early cancers may require only a small, localised removal, while more advanced tumours typically require removing a section of the bowel along with the nearby lymph nodes. For rectal cancers specifically, knowing exactly how close the tumour is to the muscle ring controlling bowel movements (the anal sphincter) helps determine whether treatment before surgery could make the operation safer and improve the chances of keeping that muscle intact.
Chemotherapy Decisions
Post-surgery chemotherapy is routinely recommended for Stage III colorectal cancer to help manage and reduce the risk of the cancer returning. For Stage II cancer, the decision is more personalised. Chemotherapy may be considered if the tissue examined after surgery shows higher-risk features, including a T4 tumour that has grown through the bowel wall, poorly formed cancer cells (poorly differentiated histology), cancer cells found within blood or lymph vessels (lymphovascular invasion), cancer cells tracking along nerves (perineural invasion), a blocked bowel at the time of diagnosis, fewer than 12 lymph nodes examined by the pathologist, a torn or perforated bowel, or surgical margins that are close to or unclear of cancer.
Radiation Therapy Role
Radiotherapy plays an important role in treating rectal cancer but is rarely used for colon cancer. When given before surgery, it can shrink the tumour to make the operation more straightforward, lower the chance of the cancer coming back in the same area, and in some cases improve the likelihood that the bowel function-controlling muscle can be preserved.
Clinical Versus Pathological Staging
Clinical staging (marked with the prefix “c”) is based on what doctors find from scans and examinations before surgery. Pathological staging (marked with the prefix “p”) is based on what the specialist finds when the removed tissue is examined in the laboratory after surgery.
These two assessments do not always match. Pre-operative scans can miss small amounts of cancer in lymph nodes, or can flag lymph nodes as suspicious when they are simply enlarged due to inflammation rather than cancer.
When pathological staging is available, it generally provides a more complete and reliable picture for planning further treatment and understanding likely outcomes.
Molecular Testing and Staging
In addition to staging based on anatomy (how far the cancer has spread physically), doctors now routinely look at the genetic and molecular features of the cancer cells themselves. These findings increasingly influence which treatments are chosen.
MSI/MMR testing (checking whether the cancer cells have a faulty DNA repair system) is now a standard test. If the cancer has this fault, described as MSI-H or dMMR, it has important treatment implications. In Stage II disease, these tumours are generally not recommended for standard post-surgery chemotherapy, as evidence suggests it is unlikely to help and may even be harmful. In advanced or metastatic disease, these tumours respond well to a type of treatment called immunotherapy (medicines that help the body’s own immune system recognise and attack cancer cells), such as pembrolizumab or nivolumab, which are now recommended treatment options for eligible patients.
RAS and BRAF gene testing is performed in patients with metastatic disease to guide the choice of targeted medicines. These gene changes affect whether certain treatments, particularly a group of medicines called anti-EGFR antibodies, will work or not, so testing is done before treatment begins.
HER2 testing is recommended for all patients with metastatic colorectal cancer. Approximately 3–5% of colorectal cancers carry a change called HER2 amplification or overexpression. Patients whose tumours test positive for HER2, and who do not have RAS or BRAF mutations, may be eligible for targeted HER2 medicines, including an approved combination of tucatinib and trastuzumab.
Preparing for Your Staging Discussion
Gather your medical records. Bring previous colonoscopy reports, scan results, and biopsy findings to your appointments. Having everything in one place helps ensure your specialist has the full picture.
Write down your questions before your appointment. Most patients want to understand what further tests are still needed, how the results affect their treatment choices, and what the likely timeline looks like.
Consider bringing a support person when attending appointments where staging results and treatment plans will be discussed. Having someone with you helps with taking in a lot of information at once and remembering the details afterwards.
Ask about a multidisciplinary team review for your case. Colorectal cancer is best managed with input from specialists across different fields, including surgeons, cancer medicine doctors, radiation specialists, and radiologists who interpret the scans, all working together on your care plan.
When to Seek Professional Evaluation
- Unexplained changes in bowel habits (such as looser stools, constipation, or a change in stool consistency) lasting more than a few weeks
- Blood in the stool or rectal bleeding
- Ongoing abdominal discomfort, cramping, or bloating that does not go away
- Unintentional weight loss
- Unusual or persistent tiredness that does not improve with rest
- A family history of colorectal cancer, particularly in close relatives diagnosed at a younger age
Commonly Asked Questions
How long does the staging process take?
In most cases, staging can be completed within a short period once imaging and biopsy results are available. More complex cases requiring additional specialised tests may take a little longer. Your medical team will keep you informed of the timeline and will move as quickly as appropriate.
Can staging change after treatment begins?
Yes. If treatment is given before surgery to shrink the tumour, doctors will reassess the stage based on how the cancer has responded. If surgery uncovers more disease than the scans suggested, the stage is updated accordingly. This ongoing reassessment ensures treatment reflects the most current understanding of your cancer.
Does a higher stage always mean worse outcomes?
Not necessarily. While the stage provides a general indication of how advanced the cancer is, individual factors, including the specific biology of the tumour, its response to treatment, and the person’s overall health, all play a significant role. Staging provides a useful framework for planning, rather than a fixed prediction. Your doctor is best placed to discuss what your particular stage means for you.
What if cancer is found in the lymph nodes during surgery, when it was not detected beforehand?
This is called upstaging, and it occurs when detailed examination of the removed tissue reveals more spread than the preoperative scans showed. When this occurs, the treatment plan is revised accordingly. For example, chemotherapy may be recommended even if it was not initially planned.
How often will I need re-assessment during treatment?
This depends on your treatment plan. During active treatment, imaging scans are typically repeated at set intervals to check how well the cancer is responding. After treatment ends, regular follow-up visits with scans and CEA blood tests help detect any signs of the cancer returning as early as possible.
Next Steps
Staging maps out how far colorectal cancer has spread, looking at the depth of the tumour, the lymph nodes, and whether distant organs are involved, and each of these findings directly shapes surgical and treatment decisions. The results from tissue examined after surgery typically offer the most accurate picture.
For Stage II and III cancers in particular, the specific features observed in the tissue sample, alongside molecular test results such as MSI/MMR and RAS/BRAF status, can meaningfully change the recommended treatment. This is why thorough and complete staging is so important before any treatment plan is finalised.
If you have received a colorectal cancer diagnosis, or are experiencing blood in your stool, persistent changes in bowel habits, or unexplained abdominal discomfort, formal medical evaluation and specialised clinical consultations are available to undergo a full staging assessment and discuss the most appropriate treatment options for your situation.
